Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

The sustained benefit of immunotherapy-based regimens in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure is debatable. Neither Checkmate-722 nor Keynote-789 reached the prespecified statistical level of clinical be...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Wu, Yan Ling, Bao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Yuan-Sheng Zang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/4/e008818.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
by: Zhixin Chen, et al.
Published: (2025-12-01)

Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations
by: Atsuto Mouri, et al.
Published: (2025-07-01)

Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
by: Lianxi Song, et al.
Published: (2025-09-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
by: Yiming ZENG, et al.
Published: (2025-06-01)

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2025-05-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01)

Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
by: Die Zhang, et al.
Published: (2025-12-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia
by: Elisna Syahruddin, et al.
Published: (2025-01-01)

The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer
by: Xiao Yang, et al.
Published: (2018-09-01)

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer
by: Yuhong Ma, et al.
Published: (2024-12-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma
by: Fangfang Yang, et al.
Published: (2025-05-01)

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
by: Kimio Yonesaka, et al.
Published: (2025-03-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.
by: Marzena Anna Lewandowska, et al.
Published: (2015-01-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)

Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.
by: Ming-Szu Hung, et al.
Published: (2017-01-01)

Letter to the Editor: EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
by: Hinpetch Daungsupawong PhD, et al.
Published: (2024-10-01)

Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study
by: Dao TV, et al.
Published: (2025-04-01)

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation
by: Kaibo Ding, et al.
Published: (2025-03-01)

EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.
by: Vanita Noronha, et al.
Published: (2013-01-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
by: Ryan Cooper, et al.
Published: (2024-11-01)

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
by: Nazia Chaudhary, et al.
Published: (2025-02-01)

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
by: Jietao Ma, et al.
Published: (2024-10-01)

Exploring new frontiers in lung cancer treatment: The role of cancer‐associated fibroblasts (CAFs) and EGFR‐TKI resistance
by: Jiaqi Liang, et al.
Published: (2025-04-01)

MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway
by: Saiqun Zhang, et al.
Published: (2025-07-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
by: Rui FAN, et al.
Published: (2025-05-01)

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01)

Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
by: Eva Yu-Hsuan Chuang, et al.
Published: (2025-04-01)

Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
by: Meejeong Kim, et al.
Published: (2025-04-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
by: Alfredo Addeo
Published: (2022-06-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)